Joseph Catanzaro
Stock Analyst at Mizuho Securities
(4.61)
# 935
Out of 4,673 analysts
418
Total ratings
46%
Success rate
13.3%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Maintained: Hold | $18 → $20 | $23.90 | -16.32% | 2 | Aug 13, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $215 | $209.46 | +2.64% | 17 | Aug 5, 2026 | |
| TNGX Tango Therapeutics | Maintained: Buy | $36 → $40 | $23.88 | +67.50% | 9 | Jul 17, 2026 | |
| KYMR Kymera Therapeutics | Maintained: Buy | $140 | $119.80 | +16.86% | 3 | Jul 16, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $84 → $120 | $106.49 | +12.69% | 4 | Jul 13, 2026 | |
| QTTB Q32 Bio | Reiterated: Buy | $14 → $36 | $15.97 | +125.42% | 2 | Jul 13, 2026 | |
| NRIX Nurix Therapeutics | Maintained: Buy | $30 → $34 | $26.72 | +27.25% | 27 | Jul 13, 2026 | |
| APGE Apogee Therapeutics | Downgraded: Hold | $110 → $135 | $134.75 | +0.19% | 9 | Jun 24, 2026 | |
| AVTX Avalo Therapeutics | Maintained: Buy | $39 → $45 | $19.83 | +126.93% | 3 | May 14, 2026 | |
| UPB Upstream Bio | Maintained: Buy | $51 → $50 | $6.97 | +617.36% | 2 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $26 | $17.63 | +47.48% | 4 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $21.04 | +137.64% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $17.28 | +4.17% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $11.39 | +128.27% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $40.38 | +18.87% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.5 | $0.5001 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $38 | $4.68 | n/a | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.25 | $3.28 | n/a | 15 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $53 | $108.17 | n/a | 27 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4.75 → $4.25 | $7.79 | n/a | 15 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $0.8801 | n/a | 16 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 → $6 | $8.29 | n/a | 37 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $45 | $19.71 | n/a | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $38 | $54.08 | n/a | 11 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $110 | $146.12 | n/a | 20 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $3 | $1.42 | n/a | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $15 | $11.03 | n/a | 25 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 | $8.93 | n/a | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $19 | $1.37 | n/a | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $2.21 | n/a | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $2.00 | n/a | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $2.21 | n/a | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $1.75 | $4.73 | n/a | 9 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $3.00 | n/a | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $11.08 | n/a | 39 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $1.75 | $0.8455 | n/a | 8 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1.75 | $2.36 | n/a | 4 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $38.63 | n/a | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $1.39 | n/a | 3 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $4 | $32.00 | n/a | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 → $36 | $14.68 | n/a | 4 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $1.52 | n/a | 7 | Aug 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $18 | $2.28 | n/a | 4 | Apr 7, 2020 |
Bicara Therapeutics
Aug 13, 2026
Maintained: Hold
Price Target: $18 → $20
Current: $23.90
Upside: -16.32%
Revolution Medicines
Aug 5, 2026
Reiterated: Buy
Price Target: $215
Current: $209.46
Upside: +2.64%
Tango Therapeutics
Jul 17, 2026
Maintained: Buy
Price Target: $36 → $40
Current: $23.88
Upside: +67.50%
Kymera Therapeutics
Jul 16, 2026
Maintained: Buy
Price Target: $140
Current: $119.80
Upside: +16.86%
Spyre Therapeutics
Jul 13, 2026
Maintained: Buy
Price Target: $84 → $120
Current: $106.49
Upside: +12.69%
Q32 Bio
Jul 13, 2026
Reiterated: Buy
Price Target: $14 → $36
Current: $15.97
Upside: +125.42%
Nurix Therapeutics
Jul 13, 2026
Maintained: Buy
Price Target: $30 → $34
Current: $26.72
Upside: +27.25%
Apogee Therapeutics
Jun 24, 2026
Downgraded: Hold
Price Target: $110 → $135
Current: $134.75
Upside: +0.19%
Avalo Therapeutics
May 14, 2026
Maintained: Buy
Price Target: $39 → $45
Current: $19.83
Upside: +126.93%
Upstream Bio
May 14, 2026
Maintained: Buy
Price Target: $51 → $50
Current: $6.97
Upside: +617.36%
May 12, 2026
Maintained: Buy
Price Target: $28 → $26
Current: $17.63
Upside: +47.48%
Apr 30, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $21.04
Upside: +137.64%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $17.28
Upside: +4.17%
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $11.39
Upside: +128.27%
Jan 9, 2026
Reiterated: Buy
Price Target: $48
Current: $40.38
Upside: +18.87%
Mar 21, 2025
Maintained: Buy
Price Target: $4.5
Current: $0.5001
Upside: n/a
Mar 20, 2025
Maintained: Buy
Price Target: $36 → $38
Current: $4.68
Upside: n/a
Mar 7, 2025
Maintained: Buy
Price Target: $3.25
Current: $3.28
Upside: n/a
Mar 6, 2025
Maintained: Hold
Price Target: $53
Current: $108.17
Upside: n/a
Mar 3, 2025
Maintained: Hold
Price Target: $4.75 → $4.25
Current: $7.79
Upside: n/a
Feb 28, 2025
Maintained: Buy
Price Target: $10
Current: $0.8801
Upside: n/a
Feb 28, 2025
Maintained: Hold
Price Target: $7.5 → $6
Current: $8.29
Upside: n/a
Feb 27, 2025
Maintained: Buy
Price Target: $50 → $45
Current: $19.71
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $37 → $38
Current: $54.08
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $105 → $110
Current: $146.12
Upside: n/a
Jan 29, 2025
Rated: Buy
Price Target: $15 → $3
Current: $1.42
Upside: n/a
Jan 17, 2025
Maintained: Buy
Price Target: $40 → $15
Current: $11.03
Upside: n/a
Nov 6, 2024
Rated: Buy
Price Target: $19
Current: $8.93
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $10 → $19
Current: $1.37
Upside: n/a
Oct 8, 2024
Rated: Buy
Price Target: $15
Current: $2.21
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: $10 → $8
Current: $2.00
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $30
Current: $2.21
Upside: n/a
Aug 27, 2024
Downgraded: Hold
Price Target: $5 → $1.75
Current: $4.73
Upside: n/a
Apr 22, 2024
Initiated Coverage: Buy
Price Target: $20
Current: $3.00
Upside: n/a
Apr 8, 2024
Maintained: Buy
Price Target: $15
Current: $11.08
Upside: n/a
May 23, 2023
Downgraded: Hold
Price Target: $15 → $1.75
Current: $0.8455
Upside: n/a
Sep 14, 2022
Maintained: Hold
Price Target: $1.5 → $1.75
Current: $2.36
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $6
Current: $38.63
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $15
Current: $1.39
Upside: n/a
May 12, 2022
Maintained: Buy
Price Target: $10 → $4
Current: $32.00
Upside: n/a
Mar 9, 2022
Maintained: Buy
Price Target: $45 → $36
Current: $14.68
Upside: n/a
Aug 21, 2020
Maintained: Buy
Price Target: $15 → $17
Current: $1.52
Upside: n/a
Apr 7, 2020
Maintained: Buy
Price Target: $28 → $18
Current: $2.28
Upside: n/a